Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases

BACKGROUND: Programmed death receptor-1 (PD-1) immune checkpoint inhibitors (ICIs) have produced encouraging results in hepatocellular carcinoma (HCC) patients. Cytokine-induced killer (CIK) cells treatment can specifically identify tumor-associated antigens and has encouraging preliminary efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tong, Zhang, Linzhi, Zeng, Zhen, Yan, Tao, Cheng, Jiamin, Miao, Xiaojie, Lu, Yinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702989/
https://www.ncbi.nlm.nih.gov/pubmed/34984004
http://dx.doi.org/10.2147/OTT.S333604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702989/
https://www.ncbi.nlm.nih.gov/pubmed/34984004
http://dx.doi.org/10.2147/OTT.S333604

Ejemplares similares